Cefixime Use in Respiratory Infections: Evidence and Guideline Recommendations

Pharmacokinetic Limitations

Activity Against Resistant Streptococcus pneumoniae

Guideline Recommendations for Outpatient Lower Respiratory Tract Infections

Guideline Recommendations for Hospitalized Pneumonia

FDA‑Approved Indications (Non‑Respiratory)

Clinical Efficacy in Acute Exacerbations of Chronic Bronchitis

Cefixime Clinical Use Guidelines

Spectrum of Antimicrobial Activity and Clinical Use

• High urinary concentrations of cefixime are achieved with once-daily dosing due to renal excretion, making it effective for urinary tract infections 6
• The CDC recommends ceftriaxone 250 mg IM plus azithromycin 1 g orally as first-line therapy for gonorrhea; cefixime 400 mg orally plus azithromycin 1 g orally is an alternative when ceftriaxone is unavailable 7
• Cefixime provides lower and less sustained bactericidal levels than ceftriaxone, resulting in cure rates of only 97.1-97.4% for urogenital/anorectal gonorrhea versus 98.9-99.1% for ceftriaxone 8
• Cefixime is not recommended for pharyngeal gonorrhea due to a failure rate of 5.8% versus 1.8% for ceftriaxone-based regimens 7
• Mandatory test-of-cure at 1 week when cefixime is used due to declining susceptibility and elevated MICs 7
• Cefixime should not be used as monotherapy; it must be combined with azithromycin 7
• Cefixime functions as the standard oral cephalosporin substitute for ceftriaxone when oral therapy is appropriate, though with important limitations 8
• No empirical use of cefixime in febrile neutropenia is recommended due to its lack of anti-pseudomonal activity 9
• Never confuse ceftriaxone with cefixime, as ceftriaxone has no oral formulation and must be given IV or IM 8
• Cross-reactivity with penicillin is negligible due to different chemical structures as a third-generation agent 6